Hoth Therapeutics, Inc. (HOTH)

Hoth Therapeutics, Inc. (HOTH) Healthcare & Pipeline Overview

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for unmet medical needs, including HT-001 for skin disorders and HT-ALZ for Alzheimer's. With a focus on innovative treatments and strategic licensing agreements, Hoth operates within the competitive biotechnology sector, targeting niche therapeutic areas.

What Is the Investment Thesis for HOTH?

Hoth Therapeutics presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company's value is primarily driven by the potential success of its therapeutic pipeline, particularly HT-001 and HT-ALZ. Upcoming clinical trial results for BioLexa Platform in Phase I for eczema will be a key catalyst. The company's market capitalization of $11.63M reflects its early stage and inherent risks. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's beta of 0.60 suggests lower volatility compared to the broader market, but this does not mitigate the significant risks associated with biotechnology investments. Success in advancing its pipeline and securing partnerships will be critical for long-term value creation.

Based on FMP financials and quantitative analysis

HOTH Key Highlights

• Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on unmet medical needs.
• The company has a diverse pipeline of therapeutic candidates, including treatments for skin disorders, cancers, Alzheimer's, inflammatory bowel diseases, asthma, lung diseases, COVID-19, eczema and lupus.
• Hoth Therapeutics has strategic license agreements with multiple universities and research institutions.
• The company's lead candidate, HT-001, targets rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy.
• Hoth Therapeutics has a market capitalization of $11.63M and a beta of 0.60.

Who Are HOTH's Competitors?

HOTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HOTH's Key Strengths?

• Diverse pipeline of therapeutic candidates.
• Strategic license agreements with universities and research institutions.
• Proprietary drug compound platform (BioLexa Platform).
• Focus on unmet medical needs.

What Are HOTH's Weaknesses?

• Clinical-stage company with no approved products.
• Limited financial resources.
• Small number of employees.
• High dependence on clinical trial outcomes.

What Could Drive HOTH Stock Higher?

• Clinical trial results for BioLexa Platform in Phase I for eczema.
• Advancement of HT-ALZ through preclinical and clinical development for Alzheimer's disease.
• Progress in securing additional license agreements for novel therapeutic candidates.
• Potential partnerships with pharmaceutical companies for commercialization of its products.

What Are the Key Risks for HOTH?

• Financial-distress signal — its Altman Z-Score of -20.08 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key therapeutic candidates.
• Regulatory hurdles and delays in obtaining approval for its products.
• Competition from larger pharmaceutical companies with greater resources.
• Need for additional funding to support its operations and development programs.
• Dependence on the success of its pipeline and the ability to secure partnerships.

What Are the Growth Opportunities for HOTH?

• Advancement of BioLexa Platform for Eczema Treatment: Hoth's BioLexa Platform, currently in Phase I clinical trials for eczema, represents a significant growth opportunity. The global eczema market is projected to reach $13.6 billion by 2033. Positive clinical trial results and subsequent regulatory approval could drive substantial revenue growth for Hoth. The company's patented drug compound platform provides a competitive advantage in this space, potentially leading to strategic partnerships and licensing agreements.
• Development of HT-ALZ for Alzheimer's Disease: HT-ALZ, Hoth's therapeutic candidate for Alzheimer's disease, addresses a critical unmet medical need. The global Alzheimer's disease market is expected to reach $12.78 billion by 2032. Successful development and commercialization of HT-ALZ could generate significant revenue. Hoth's focus on neuroinflammatory diseases positions it to capitalize on the growing demand for effective Alzheimer's treatments, offering a potential first-mover advantage.
• Expansion of HT-003 for Inflammatory Bowel Diseases: Hoth's HT-003 targets inflammatory bowel diseases (IBD), as well as acne and psoriasis, representing a diversified growth opportunity. The global IBD market is projected to reach $24.5 billion by 2033. Positive clinical data and regulatory approval could drive adoption of HT-003. Hoth's research collaboration with Weill Cornell Medicine enhances its capabilities in this area, potentially leading to a differentiated product offering.
• Commercialization of HT-001 for Skin Disorders: HT-001, a topical formulation for skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy, offers a targeted growth opportunity. The market for treatments of skin disorders is substantial, with ongoing demand for effective therapies. Successful commercialization of HT-001 could generate revenue through direct sales and partnerships with oncology clinics and dermatology practices.
• Strategic Partnerships and Licensing Agreements: Hoth's strategy of securing license agreements with universities and research institutions provides a continuous pipeline of innovative therapeutic candidates. These partnerships allow Hoth to access cutting-edge research and technologies, accelerating the development of its portfolio. Future licensing agreements and collaborations could expand Hoth's pipeline and diversify its revenue streams, reducing reliance on any single therapeutic candidate.

What Opportunities Does HOTH Have?

• Successful clinical trial results for key therapeutic candidates.
• Regulatory approval and commercialization of its products.
• Expansion of its pipeline through additional license agreements.
• Strategic partnerships with pharmaceutical companies.

What Threats Does HOTH Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger pharmaceutical companies.
• Need for additional funding.

What Are HOTH's Competitive Advantages?

• Proprietary drug compound platform (BioLexa Platform).
• Strategic license agreements with leading universities and research institutions.
• Focus on developing therapies for unmet medical needs.
• Pipeline of therapeutic candidates targeting a range of diseases.

What Does HOTH Do?

Hoth Therapeutics, Inc., incorporated in 2017 and headquartered in New York City, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs. The company's pipeline includes a range of therapeutic candidates targeting various diseases. Its lead candidate, HT-001, is a topical formulation designed to treat rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy. Other key programs include HT-KIT for mast-cell derived cancers and anaphylaxis, HT-ALZ for Alzheimer's disease, HT-003 for inflammatory bowel diseases, acne, and psoriasis, HT-004 for asthma and allergies, HT-006 for lung diseases resulting from bacterial infections, HT-002 for COVID-19, BioLexa Platform for eczema, and HT-005 for lupus. Hoth leverages strategic license agreements with institutions such as the George Washington University, the University of Maryland, Isoprene Pharmaceuticals, Inc., the North Carolina State University, Chelexa BioSciences, Inc., Zylö Therapeutics, Inc., and the University of Cincinnati, as well as a research collaboration agreement with Weill Cornell Medicine to develop HT-003. These partnerships enable Hoth to access cutting-edge research and technologies, accelerating the development of its therapeutic pipeline. The company's focus on addressing unmet medical needs positions it within the competitive biotechnology landscape, where it aims to deliver novel treatments and improve patient outcomes.

What Products and Services Does HOTH Offer?

• Develops HT-001, a topical formulation for skin disorders associated with tyrosine kinase inhibitor therapy.
• Develops HT-KIT to treat mast-cell derived cancers and anaphylaxis.
• Develops HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases.
• Develops HT-003 to treat inflammatory bowel diseases, acne, and psoriasis.
• Develops HT-004 for treatment of asthma and allergies using inhalational administration.
• Develops HT-006 to treat lung diseases resulting from bacterial infections.
• Develops HT-002, a novel peptide for treating COVID-19.
• Develops BioLexa Platform, a proprietary drug compound platform for the treatment of eczema.

How Does HOTH Make Money?

• Develops therapeutic candidates for unmet medical needs.
• Secures license agreements with universities and research institutions to access innovative technologies.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
• Seeks regulatory approval from agencies such as the FDA to commercialize its products.
• Potentially commercializes its products through direct sales, partnerships, or licensing agreements.

What Industry Does HOTH Operate In?

Hoth Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The industry is driven by the increasing demand for novel therapies to address unmet medical needs. Hoth's focus on developing treatments for a range of diseases, including skin disorders, Alzheimer's, and inflammatory bowel diseases, positions it within specific niches of the broader pharmaceutical market. The company competes with both large pharmaceutical companies and smaller biotech firms, requiring a strategic focus on innovation and partnerships to succeed. The biotechnology industry is experiencing growth, driven by technological advancements and increasing healthcare expenditures.

Who Are HOTH's Key Customers?

• Patients suffering from skin disorders associated with tyrosine kinase inhibitor therapy.
• Patients with mast-cell derived cancers and anaphylaxis.
• Patients with Alzheimer's disease or other neuroinflammatory diseases.
• Patients with inflammatory bowel diseases, acne, and psoriasis.
• Patients with asthma and allergies.

F-Score 1/9Financial Health

Hoth Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.08 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -45.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -74.9%, the inverse of the P/E and a quick read on earnings relative to price.

Hoth Therapeutics, Inc. (HOTH) Valuation Context

Valued at $11.63M, HOTH is classified as a micro-cap stock. Relative to its peer group, HOTH's quantitative score of 27/100 is below the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project Hoth Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.59.

HOTH Financials

HOTH Latest News

HOTH Analyst Consensus

HOTH MoonshotScore

What Investors Ask About Hoth Therapeutics, Inc. (HOTH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources